Publication

Video

Special Issues

Developments in NRG1 Fusion+ Cancers
Volume1
Issue 1

Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung Adenocarcinoma

Khaled A. Tolba, MD, MBBCh, discusses the use of afatinib in NRG1 fusion–positive lung adenocarcinoma.

Khaled A. Tolba, MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the use of afatinib (Gilotrif) in NRG1 fusion—positive lung adenocarcinoma.

The TAPUR study is an umbrella trial aimed at matching patients with specific gene mutations, chromosomal transformations or driver mutations with personalized treatment, explains Tolba.

Recently, afatinib has been added to the TAPUR trial for use in NRG1-mutant lung cancer because it appears there is activity with this treatment, says Tolba. This is particularly important because there are no FDA-approved therapies for this disease,nor any targeted agents for patients with NGR1 fusions.

Pan-ERBB TKIs like afatinib are aimed downstream by targeting ERBB3 and ERBB4. The hope is to target the active ligand and ultimately benefit this particular patient population.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center